In light of the Teva/Gilead-judgment handed down on 25 July 2018 by the CJEU (C-121/17) as well as the latest referral from the German Federal Patent Court dated 17 October 2017 in re Sitagliptin III (14 W (pat) 12/17), which is pending as C-650/17, Prof. Meier-Beck, the presiding Judge of the German Federal Supreme Court,…

The preparations for the Unified Patent Court are going on so the court can start functioning as soon as possible if the German Constitutional Court rejects the challenges to the Unitary Patent project. The UPC Preparatory Committee has declared this in an update which was published on its website on 19 december 2018. It is…

The U.S. Court of Appeals for the Federal Circuit has affirmed a $139.8 million jury verdict in favor of Sprint Communications against Time Warner for infringement of five Sprint patents related to VoIP technology. The appeals court concluded that the district properly admitted evidence relating to the jury verdict in an earlier, related case brought…

The European Patent Office has opened an online consultation on the possibility of allowing more flexibility in the timing of the examination process by offering means to postpone the examination of European patent applications. The reasons for the consultation are explained on the EPO’s website: ‘Since the launch of the Early Certainty initiative in 2014,…

The Court of Appeal overturned the Patent Court’s first instance decision concerning the validity of one of ICOS’s patents (licensed to Eli Lilly) covering a 1 to 5mg dosage form of tadalafil (Cialis®) for oral administration up to a maximum of 5mg per day for the treatment of sexual dysfunction.  The Court held that the…

The number of inventive step attacks in opposition procedures at the European Patent Office may be constrained in the future due to a recent change in the EPO Guidelines. According to David Brophy, partner at FRKelly, the change will improve efficiency, although the restrictions may also open up a new avenue for criticising decisions on…

A quarter-century after supplementary protection certificates (SPCs) were introduced in the European Union, there are still a number of unresolved questions as to which types of products are, in principle, eligible for SPC protection. One further important piece in this puzzle will be provided by the CJEU’s forthcoming decision in the pending referral Abraxis Bioscience…

In a Judgment dated 26 July 2018, the influential Barcelona Court of Appeal (Section 15) rejected an overly narrow, “literalistic” interpretation of a patent claim. A claim’s terms must be interpreted according to the meaning that a person skilled in the art would give them – even if it is not the most scientifically “puristic”…